What's the deal with the conflicting order from a federal judge in Washington

Danco could also apply again for FDA approval, but it's unclear what data would be required to support a new application, given the unprecedented nature of the lawsuit and Kacsmaryk's decision. Health policy experts aren't sure if Danco would need to apply for approval under a new indication, submit new trial data, or if the company could rely on data from the 20 years the drug has been on the market. เว็บเดิมพันออนไลน์